Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | PPARG | P37231 | 7/20 | 0.63 |
| ▸ | F7 | P08709 | 7/20 | 0.63 |
| ▸ | F3 | P13726 | 7/20 | 0.63 |
| ▸ | PPARD | Q03181 | 6/20 | 0.63 |
| ▸ | PPARA | Q07869 | 6/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | RXRA | P19793 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31570910 | 1.00 | MAPT (0.81) | MAPTALDH1A1PPARGF7F3 | |
| SCHEMBL15956263 | 1.00 | MAPT (0.81) | MAPTALDH1A1PPARGF7F3 | |
| SCHEMBL655399 | 1.00 | MAPT (0.81) | MAPTALDH1A1PPARGF7F3 | |
| SCHEMBL15335274 | 1.00 | MAPT (0.81) | MAPTALDH1A1PPARGF7F3 | |
| SCHEMBL15335276 | 0.94 | MAPT (0.77) | MAPTALDH1A1PPARGF7F3 | |
| SCHEMBL17547603 | 0.94 | MAPT (0.77) | MAPTALDH1A1PPARGF7F3 | |
| SCHEMBL3741569 | 0.94 | MAPT (0.77) | MAPTALDH1A1PPARGF7F3 | |
| SCHEMBL10027315 | 0.94 | MAPT (0.77) | MAPTALDH1A1PPARGF7F3 | |
| SCHEMBL3318733 | 0.94 | MAPT (0.77) | MAPTALDH1A1PPARGF7F3 | |
| SCHEMBL3741571 | 0.94 | MAPT (0.77) | MAPTALDH1A1PPARGF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113396332-B | Method for evaluating pregnancy progression and premature abortion for clinical intervention and use thereof | 斯坦福大学托管董事会 | 2025-02-11 | — | — | CN | claimed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | claimed |
| WO-2024237316-A1 | DERMAL FIBROSIS IMPROVING EFFECT OF EPOXIDIZED UNSATURATED FATTY ACID | 国立大学法人東京大学 | 2024-11-21 | — | — | WO | claimed |
| US-20240173285-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-05-30 | — | — | US | claimed |
| EP-4329742-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-03-06 | — | — | EP | claimed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | claimed |
| WO-2022232633-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-11-03 | — | — | WO | claimed |
| US-20250388941-A1 | POLYPEPTIDE, OXYGENASE, AND APPLICATION THEREOF | AMANO ENZYME INC. (JP) | 2025-12-25 | — | — | US | disclosed |
| CN-119069037-B | Detection method of heart failure detection biomarker based on oxidized lipid derivatization and machine learning model | 中国中医科学院医学实验中心 | 2025-02-14 | — | — | CN | disclosed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | disclosed |
| CN-119069037-A | Detection method of heart failure detection biomarker based on oxidized lipid derivatization and machine learning model | 中国中医科学院医学实验中心 | 2024-12-03 | — | — | CN | disclosed |
| WO-2024237316-A1 | DERMAL FIBROSIS IMPROVING EFFECT OF EPOXIDIZED UNSATURATED FATTY ACID | 国立大学法人東京大学 | 2024-11-21 | — | — | WO | disclosed |
| US-20240173285-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-05-30 | — | — | US | disclosed |
| US-20240165066-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-05-23 | — | — | US | disclosed |
| EP-4329742-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024004921-A1 | POLYPEPTIDE, OXYGENASE, AND USE APPLICATIONS THEREOF | 天野エンザイム株式会社 | 2024-01-04 | — | — | WO | disclosed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | disclosed |
| WO-2022232633-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165066-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | LTA, ALOX5, LIPG | MAPT 4792/4885ALDH1A1 2505/4885PPARG 136/4885 |
| US-20250388941-A1 | POLYPEPTIDE, OXYGENASE, AND APPLICATION THEREOF | ELOVL3, ELOVL1, FASN | MAPT 4867/4885ALDH1A1 2274/4885PPARG 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.